Organization, Agent, Virus/Disease and Keyword Indexes to news articles from 1995 issues of the Antiviral Agents Bulletin are presented below.
Aaron Diamond Center for AIDS Research - Dec., p. 362
Aastrom Biosciences, Inc. - Nov., p. 330
Abbott Labs. - Feb., p. 38; Mar., p. 72; Apr., p. 103; July, p. 193; Oct., p. 290, 298; Dec., p. 364
Advanced BioScience Labs., Inc. - Nov., p. 333
Advanced Medical Sciences, Inc. - Apr., p. 105
Advanced Peptides Inc. - Nov., p. 329
Advanced Viral Research Corp. - Feb., p. 43
Advisory Committee on Immunization Practices (ACIP) - Feb., p. 43; July, p. 204; Aug., p. 236
AEA Technology - Apr., p. 99
Affymax Research Inst. - Sep., p. 268
Agence Nationale de Recherches sur de le Sida (ANRS) - July, p. 196
Agouron Pharmaceuticals, Inc. - Feb., p. 37; Mar., p. 72; May, p. 137; Aug., p. 232; Sep., p. 266; Oct., p. 298
AIDS Clinical Trials Group (ACTG) - Oct., p. 300; Dec., p. 364
AIDS Research Advisory Committee (ARAC) - June, p. 172
Ajinomoto Co., Inc. - Sep., p. 270
Akzo Nobel Pharma - Nov., p. 333; Dec., p. 366
Allelix Biopharmaceuticals Inc. - Feb., p. 40; Oct., p. 299
Alpha 1 Biomedicals, Inc. - Feb., p. 41; Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299
American Academy of Pediatrics - Mar., p. 65; Apr., p. 104
American Council of Life Insurance - Sep., p. 266
American Home Products Corp. - Apr., p. 100, 109; July, p. 200; Sep., p. 262; Nov., p. 327, 329; Dec., p. 361
American National Red Cross - Nov., p. 331
Amgen Corp. - May, p. 136; Aug., p. 233; Nov., p. 330
Anabolics for AIDS - June, p. 171
Aperture Associates - Feb., p. 41
Apollon, Inc. - Aug., p. 231; Dec., p. 361
Applied Immune Sciences, Inc. - Nov., p. 330
Argus Pharmaceuticals, Inc. - Mar., p. 75
Armed Forces Research Inst. of Medical Sciences - Nov., p. 332
Aronex Pharmaceuticals Inc. - Nov., p. 325, 333; Dec., p. 364
Astra USA, Inc. - July, p. 193; Sep., p. 266
Avid Therapeutics Inc. - Apr., p. 109
Aviron, Inc. - Apr., p. 108; May, p. 135; Dec., p. 363
Baker Norton Pharmaceuticals - Feb., p. 42
Barr Labs. - Apr., p. 105; June, p. 173
Baxter Healthcare Corp. - June, p. 168
Bayer AG - Nov., p. 328
Bayer Corp. - Oct., p. 295
Becton Dickinson & Co. - Nov., p. 332
Beth Israel Hospital - Sep., p. 268
BIKEN Institute - Mar., p. 65
BioChem Pharma Inc. - Feb., p. 35; Aug., p. 227; Sep., p. 262, 265; Nov., p. 321, 326
Biocontrol Technology, Inc. - May, p. 138
Biocor-Arm - Feb., p. 43
BioCryst Pharmaceuticals, Inc. - Feb., p. 41
Biogen Inc. - Feb., p. 46; Apr., p. 104, 109; May, p. 135
Biotech Research Labs. - Nov., p. 333; Dec., p. 364
Biotechnology Industry Organization - Feb., p. 45
Biotechnology Investments Ltd. - Feb., p. 41
Bock Pharmacal Co. - Apr., p. 105
Boehringer Ingelheim GmbH - Apr., p. 103
Boehringer Mannheim GmbH - Feb., p. 38; Mar., p. 77; Sep., p. 263; Nov., p. 327
Bristol-Myers Squibb Co. - Mar., p. 76; May, p. 130; June, p. 168; Aug., p. 236; Sep., p. 257, 263; Oct., p. 289; Nov., p. 331
British Biotech Pharmaceuticals - July, p. 197
British High Court of Appeals - Dec., p. 366
Burroughs Wellcome Co. (see also Glaxo Wellcome and Wellcome entries) - Feb., p. 35, 36, 40
Cambridge Biotech Corp. - Sep., p. 266, 269; Nov., p. 333; Dec., p. 364
Cangene Corp. - Dec., p. 366
Cantab Pharmaceuticals PLC - Oct., p. 301
Carrington Labs. Inc. - Aug., p. 236
CEL-SCI Corp. - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Nov., p. 331
Cell Genesys, Inc. - Sep., p. 265; Nov., p. 328
Centers for Disease Control and Prevention (CDC) - Feb., p. 38, 43, 44; Mar., p. 65, 77; July, p. 204, 205; Aug., p. 236
Centocor, Inc. - July, p. 198
Cheil Foods and Chemicals, Inc. - Feb., p. 41
Chiron Corp. - Feb., p. 44; Mar., p. 70, 77; Apr., p. 98; May, p. 134, 141, 142; July, p. 202; Sep., p. 260, 270; Oct., p. 291, 292, 296; Nov., p. 335; Dec., p. 366
Chiron Vision Corp. - Feb., p. 39; Dec., p. 357
Collagen Corp. - Feb., p. 46
Columbia Laboratories, Inc. - July, p. 201
Commonwealth Serum Labs. - Feb., p. 41
Community Programs for Clinical Res. on AIDS (CPCRA) - Oct., p. 300
Community Research Initiative on AIDS - Apr., p. 105
Connaught Labs. (see also Pasteur-Merieux Group) - June, p. 164, 169; July, p. 196; Sep., p. 270
Corange Ltd. - Nov., p. 327
Corixa Corp. - Dec., p. 363
Cryopharm Corp. - Sep., p. 270
CSL Ltd. - Feb., p. 41
CW Group - Feb., p. 41
Cytel Corp. - Oct., p. 300; Nov., p. 330
CytoDyn, Inc. - Oct., p. 297
CytRx Corp. - Sep., p. 270; Nov., p. 335
Dana-Farber Cancer Inst. - May, p. 133, 134
District Court of The Hague - May, p. 141
Domain Associates - Feb., p. 41
Dow Chemical Co. - May, p. 139
DuPont Merck Pharmaceuticals - Mar., p. 72
Emisphere Technologies, Inc. - June, p. 169; Nov., p. 331
Epitope, Inc. - May, p. 142
Epoch Pharmaceuticals - Nov., p. 332
Food and Drug Administration (FDA) - Feb., p. 36, 37, 42, 43; Mar., p. 65, 67; May, p. 138, 140; July, p. 204; Aug., p. 225, 228, 230; Sep., p. 260, 266, 267; Nov., p. 321, 323, 324; Dec., p. 353, 364
Fujimoto Diagnostics, Inc. - Feb., p. 46
Gallo, R.C. - Feb., p. 42; June, p. 166
Genelabs Tech., Inc. - Feb., p. 38; Mar., p. 77; May, p. 142; Sep., p. 263
Genentech, Inc. - May, p. 139; Sep., p. 260
Genetic Therapy, Inc. - Apr., p. 107; July, p. 199
Genetics Institute - July, p. 200; Nov., p. 329
Genetics Systems - Sep., p. 269
Genta Inc. - Apr., p. 102
Georgetown Univ. Medical Center - Dec., p. 360
Getty, J. - Aug., p. 230
Gilead Sciences, Inc. - Feb., p. 38; May, p. 132, 133; Sep., p. 260; Oct., p. 292; Nov., p. 325
Glaxo PLC - Feb., p. 34, 35; Mar., p. 71
Glaxo Wellcome Co./Glaxo Wellcome PLC (see also Burroughs Wellcome) - Mar., p. 72, 76; Apr., p. 101, 103; May, p. 135, 140; June, p. 170, 171, 173; Aug., p. 225, 227, 233, 236; Sep., p. 257, 262, 266; Oct., p. 289; Nov., p. 321, 326; Dec., p. 356, 363, 365
Hanbro Group - May, p. 135
Harlan Sprague Dawley Inc. - Nov., p. 336
Harvard Medical School - May, p. 133
Harvard Univ. - May, p. 134; July, p. 194
Health Insurance Association of America - Sep., p. 266
HemaCare Corp. - Feb., p. 40
HemaSure Inc. - Nov., p. 331
Hoechst AG - May, p. 139; Nov., p. 328; Dec., p. 364
Hoechst Marion Roussel - Nov., p. 328
Hoffmann-La Roche AG - May, p. 139; July, p. 195; Oct., p. 289
Hoffmann-La Roche Inc. - Feb., p. 33, 39, 45; Mar., p. 72; Apr., p. 103; May, p. 139; June, p. 161; July, p. 202, 203; Aug., p. 235; Sep., p. 257, 264, 267, 267, 279; Oct., p. 290, 295, 298, 299; Nov., p. 323, 324, 329; Dec., p. 353, 357
Hospital San Jorge - Oct., p. 296
Houghton Pharmaceuticals, Inc. - May, p. 140; Sep., p. 268
Hybridon Inc. - Feb., p. 41
ICN Pharmaceuticals Inc. - Mar., p. 75; Aug., p. 234
IDT, Inc. - May, p. 138
Immune Response Corp. - Feb., p. 37; Mar., p. 74; June, p. 170; Oct., p. 298
Immuno AG - May, p. 137
Immusol, Inc. - Mar., p. 76; Apr., p. 99
Indiana Univ. - Sep., p. 268
Institut National de Transfusion Sanguine - July, p. 198
Institut Pasteur - May, p. 136; Sep., p. 269
Institute of Human Virology - June, p. 166; Dec., p. 358
Institute of Medicine, NAS - Mar., p. 76; May, p. 140
Inter-Company Collaboration for AIDS Drug Development (ICC) - Apr., p. 103; Dec., p. 363
Interferon Sciences, Inc. - Feb., p. 46; May, p. 139; June, p. 169; Dec., p. 360
International Agency for Research on Cancer (IARC) - June, p. 163
International Biological Study on Cervical Cancer (IBSCC) - June, p. 163
International Murex Technologies Corp. - May, p. 141; Dec., p. 366
Intracel Corp. - Sep., p. 267
Isis Pharmaceuticals, Inc. - May, p. 131; Oct., p. 293; Nov., p. 335
Ivax Corp. - Feb., p. 42
Jagotec AG - Apr., p. 102
Japan Energy - Mar., p. 72
Japan Tobacco Inc. - May, p. 137; Sep., p. 266
Jefferson Medical College - Sep., p. 268
Johnson & Johnson Co. (see Ortho Diagnostic Systems)
Karolinska Inst. - July, p. 198
Kissei Pharmaceutical Co., Ltd. - Mar., p. 72; May, p. 140
Kleiner Perkins Caulfield and Byers - Feb., p. 41
Lederle-Praxis Biologicals - Sep., p. 262
Lehigh Univ. - Sep., p. 270
LIDAK Pharmaceuticals - May, p. 137, 138; Oct., p. 293
Liposome Co., The - Apr., p. 109
LXR Biotechnology Inc. - Nov., p. 333
Marion Merrell Dow Inc. - May, p. 139
Massachusetts General Hospital - Oct., p. 300
Matrix Pharmaceutical, Inc. - Feb., p. 46; Sep., p. 264; Dec., p. 364
Medeva PLC - Nov., p. 335
MediChem Research Inc. - Oct., p. 300
MedImmune, Inc. - Apr., p. 97; June, p. 165, 168; Aug., p. 228; Nov., p. 327, 335; Dec., p. 360, 364
Memorial Sloan Kettering Cancer Center - Sep., p. 279
Merck & Co. - Feb., p. 41; Mar., p. 65, 72, 73; Apr., p. 104; May, p. 129; July, p. 203, 204; Aug., p. 233; Oct., p. 291, 298
Michigan Dept. of Public Health - Sep., p. 267
MicroGeneSys, Inc. - June, p. 164
MicroProbe Corp. - Nov., p. 332
Mitotix Inc. - Apr., p. 103
Myco Pharmaceuticals - Apr., p. 99
N.P.O. Vector - Dec., p. 361
National Academy of Sciences (NAS) - Mar., p. 76; May, p. 140
National Cancer Advisory Board - June, p. 172
National Cancer Inst. (NCI) - Mar., p. 72; June, p. 172, 173; July, p. 205; Aug., p. 238; Dec., p. 358, 366
National Cooperative Drug Discovery Groups (NCDDG) - May, p. 134
National Heart, Lung and Blood Inst. (NHLBI) - Apr., p. 97
National Institute of Allergy and Infectious Diseases (NIAID) - Feb., p. 42; Mar., p. 70, 77; Apr., p. 100, 108; June, p. 172; Oct., p. 300; Dec., p. 363, 364
National Institute of Dental Research (NIDR) - May, p. 136
National Institute of Mental Health (NIMH) - Nov., p. 329
National Institutes of Health (NIH) - Feb., p. 42, 46; Apr., p. 106, 107, 109; June, p. 165, 173; July, p. 202
New York Univ. Medical Center, - Oct., p. 294
Nippon Zeon Ltd. - May, p. 140
North American Biologicals, Inc. - Sep., p. 260, 267
Novopharm, Inc. - June, p. 173
Oclassen Pharmaceuticals Inc. - Apr., p. 105
Oncologix, Inc. - Mar., p. 75
OncorPharm Inc. - July, p. 206
OncoRx Inc. - Nov., p. 334
OraVax, Inc. - Oct., p. 294
Ortho Diagnostics Systems, Inc. - Feb., p. 44; Mar., p. 77; May, p. 142; Sep., p. 263, 266; Nov., p. 335
Oxford Asymmetry - Apr., p. 99
Oxford Bioscience Partners - Feb., p. 41; Apr., p. 109
Paracelsian, Inc. - July, p. 202; Dec., p. 366
PAREXEL International Inc. - Apr., p. 103
Pasteur Sanofi Diagnostics - Sep., p. 269
Pasteur-Merieux Group - June, p. 164, 169; July, p. 196; Sep., p. 270
PathoGenesis Corp. - May, p. 135
Paul Ehrlich Institute - Dec., p. 358
Peptech (USA) - Nov., p. 329
Pfizer Inc. - Mar., p. 76; Apr., p. 99; Oct., p. 301
Pharma Bio-Research - May, p. 139
Pharma Mar S.A. - May, p. 136; Aug., p. 236
Pharmacia AB - Feb., p. 41; Sep., p. 265
Princeton University - July, p. 206
Procept, Inc. - May, p. 134
Progenics Pharmaceuticals, Inc. - June, p. 166; Nov., p. 333; Dec., p. 364
Promega Corp. - Feb., p. 45
Protein Design Labs. Inc. - Nov., p. 327
Purdue Frederick Co. - May, p. 139
Rhein Biotech AG - June, p. 171
Rhone-Poulenc Rorer Inc. - Mar., p. 74; Nov., p. 330
Rhone-Poulenc Rorer S.A. - July, p. 196; Sep., p. 270
RiboGene, Inc. - Feb., p. 41; May, p. 140; Sep., p. 268
RPR Gencell - Nov., p. 330
San Raffaele Scientific Institute - Dec., p. 358
Sandoz Ltd. - July, p. 199
Sang-A - May, p. 135
Schering-Plough Corp. - May, p. 135; Aug., p. 234
SciClone Pharmaceuticals, Inc. - Feb., p. 41; June, p. 171
Scripps Research Inst., The - Nov., p. 330
Senegal - July, p. 194
Sepracor Inc. - Nov., p. 331
Sequel Therapeutics Inc. - Nov., p. 330
Serono Labs., Inc. - Feb., p. 42
Shaman Pharmaceuticals, Inc. - June, p. 162
Sheffield Medical Technologies Inc. - Aug., p. 235
Sierra Ventures - Feb., p. 41
SmithKline Beecham Biologicals - Mar., p. 67; Oct., p. 299; Dec., p. 363
SmithKline Beecham Corp. - Apr., p. 109; May, p. 138, 142; Oct., p. 297, 302; Dec., p. 355
Somatix Therapy Corp. - Apr., p. 107
Southern Research Inst. - Sep., p. 268
Southwest Foundation for Biomedical Research - Dec., p. 364
SRA Technologies - Sep., p. 268
Strategic Program for Innovative Research on AIDS Treatment (SPIRAT) - Aug., p. 231; Oct., p. 300
Synergen, Inc. - May, p. 136
Syntex Corp. - Feb., p. 33, 39; May, p. 139
T Cell Diagnostics Inc. - July, p. 204
Tanox Biosystems, Inc. - July, p. 197; Sep., p. 268
Terrapin Technologies Inc. - Apr., p. 109
Terry Beirn Community Programs for Clinical Res. on AIDS - Oct., p. 300
Therapeutic Peptides Inc. - Nov., p. 329
Theratechnologies Inc. - Nov., p. 336
Trimeris Inc. - Oct., p. 300
Trinity Medical Group - Oct., p. 298
Triplex Pharmaceutical Corp. - Mar., p. 75
Tulane Univ. - Sep., p. 269; Oct., p. 302
UniQuest Ltd. - Feb., p. 41
United Biomedical Inc. - June, p. 170
Univax Biologics, Inc. - Sep., p. 260; Oct., p. 292
Univ. of Alabama - Feb., p. 41; Nov., p. 333
Univ. of California (San Francisco, CA) - May, p. 133; Aug., p. 230
Univ. of California (Santa Barbara, CA) - June, p. 171
Univ. of Maryland - June, p. 166
Univ. of Medicine and Dentistry of New Jersey - Sep., p. 270; Dec., p.358
Univ. of Oklahoma - Dec., p. 364
Univ. of Pennsylvania - Aug., p. 231; Oct., p. 298
Univ. of Pittsburgh - Aug., p. 230; Nov., p. 333; Dec., p. 364
Univ. of Puerto Rico - Nov., p. 333; Dec., p. 364
Univ. of Rochester - Nov., p. 335; Dec., p. 360
Univ. of Washington - Sep., p. 268
Upjohn Co. - Mar., p. 72; Sep., p. 265
U.S. Army Medical Command - July, p. 205
U.S. Army Medical Research Inst. of Infectious Diseases - Dec., p. 361
U.S. Bioscience, Inc. - Feb., p. 46
U.S. Department of Health and Human Services (DHHS) - Feb., p. 44
U.S. House of Representatives Commerce Committee - Feb., p. 42
U.S. Justice Department - June, p. 173
U.S. Patent and Trademark Office - Feb., p. 45; Mar., p. 78; Aug., p. 239
U.S. Supreme Court - June, p. 173
Vaxcel, Inc. - Sep., p. 270; Nov., p. 335
Verex Laboratories, Inc. - Dec., p. 365
Vertex Pharm. - Mar., p. 72; May, p. 140; Aug., p. 233; Dec., p. 356
Viagene, Inc. - Feb., p. 46; Apr., p. 98; Sep., p. 270; Oct., p. 296
VIMRx Pharmaceuticals Inc. - Apr., p. 104; May, p. 139
Viral Technologies, Inc. - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Dec., p. 364
Viral Therapeutics Inc. - Oct., p. 302; Dec., p. 364
Virex Inc. - June, p. 166
Virginia Commonwealth Univ. - Nov., p. 328
Virion Systems, Inc. - Sep., p. 268
Virogenetics Corp. - June, p. 164
Walter Reed Army Inst. of Research (WRAIR) - July, p. 203
Warner-Lambert Co - Feb., p. 36, 41; Dec., p. 363
Warner-Lambert Consumer Healthcare - Dec., p. 363
Weizman Inst. of Science - Sep., p. 265
Wellcome PLC (see also Glaxo Wellcome) - Feb., p. 34; Mar., p. 71
Wellcome Trust - Feb., p. 34
Whitehead Inst. - Apr., p. 107
Wistar Inst. - Oct., p. 298; Nov., p. 329
Wyeth-Ayerst Labs. - Apr., p. 100, 109; Nov., p. 327; Dec., p. 361
Xenograft Technologies, Ltd. - Sep., p. 265
XTL Biopharmaceuticals - Sep., p. 265
Yamanouchi Europe B.V. - Oct., p. 293
Yerkes Regional Primate Research Center - Nov., p. 331
Zeneca Pharmaceuticals - Mar., p. 71
Zynaxis Inc. - Sep., p. 267; Dec., p. 364
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (use ribavirin)
3TC (see also lamivudine) - June, p. 170; Aug., p. 227, 236; Sep., p. 262; Dec., p. 363
3TC plus AZT - Feb., p. 35; Aug., p. 227; Nov., p. 321
5-fluorouracil gel - Feb., p. 46; Sep., p. 264; Dec., p. 364
9-(2-phosphonylmethoxyethyl)adenine, bis pivaloyoxylmethyl- - May, p. 132
[9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine], diacetyl ester - May, p. 138
ABT-538 (use ritonavir)
AccuSite Injectable Gel - Feb., p. 46; Sep., p. 264; Dec., p. 364
acemannan - Aug., p. 236
acetylsalicylic acid - Apr., p. 105
acyclovir - Feb., p. 40; Apr., p. 101; May, p. 135; Oct., p. 294
acyclovir, cream - Oct., p. 293
acyclovir, over-the-counter - Feb., p. 36; Dec., p. 363
AD-439 - July, p. 197
AD-519 - July, p. 197
adenine, (R)-9-(2-phosphonylmethoxypropyl)- - Nov., p. 325
adenovirus gene therapy vectors - Oct., p. 298
AG1343 - Feb., p. 37; May, p. 137; Aug., p. 232; Sep., p. 266; Oct., p. 298
Alferon N Gel - June, p. 169
Alferon N Injection - Feb., p. 46; May, p. 139
ALVAC-HIV (vCP205) - June, p. 164
ALX40-4C - Feb., p. 40; Oct., p. 299
amantadine - Feb., p. 43
anabolic steroids - June, p. 171
antisense oligonucleotides - Feb., p. 41; Apr., p. 102; May, p. 131; June, p. 171; July, p. 206; Oct., p. 293; Nov., p. 332
AR-121 - Mar., p. 75; Nov., p. 325
AR132 - Nov., p. 333
AR177 - Nov., p. 325; Nov., p. 333
aspirin - Apr., p. 105
AZT - Mar., p. 76; Apr., p. 103; June, p. 171, 173; July, p. 195; Sep., p. 257, 264, 266; Oct., p. 290, 291; Dec., p. 363
AZT, controlled release (Aztec) - Apr., p. 102; Dec., p. 365
AZT, generic - Apr., p. 105
AZT-DDI dimer - Feb., p. 42
AZT plus DDC - Oct., p. 289
AZT plus DDI - Oct., p. 289
baboon bone marrow transplants - May, p. 140; Aug., p. 230
BCX-140 - Feb., p. 41
beta-propriolactone - Feb., p. 40
bichloroacetic acid - Oct., p. 296
BioLogic-HT System - May, p. 138
bis(POM)PMEA - May, p. 132
bovine peptide-nucleic acid solution - Feb., p. 43
Bucast - May, p. 139; Nov., p. 328
bupivacaine - Aug., p. 231
calanolide A - Oct., p. 300
canine oral papillomavirus vaccines - Dec., p. 360
CD4+/CD8+ T-cell monitoring systems - Sep., p. 267
CD4-based polypeptide - May, p. 134
CD4-Immunoglobulin G2 (CD4-IgG2) - June, p. 166
Cell Production System (CPS) - Nov., p. 330
cell antiviral factor (CAF) - Dec., p. 358
chemokines - Dec., p. 358
chickenpox vaccines - Apr., p. 104; July, p. 204
Chinese medicinal herbs - Dec., p. 366
cidofovir prodrug - May, p. 133
cidofovir - Feb., p. 38; May, p. 133; Sep., p. 260; Oct., p. 292
cidofovir, intravitreal - May, p. 133; Sep., p. 260
CMV antisense oligonucleotides - May, p. 131; Oct., p. 293
CMV gH humanized monoclonal antibody - Nov., p. 327
CMV vaccines - Sep., p. 260; Oct., p. 292
condyloma acuminata vaccine - Oct., p. 296
Condylox - Apr., p. 105
Croton lechleri - June, p. 162
curcumin - July, p. 205
cyclodepsipeptides - May, p. 136
cytolin - Oct., p. 297
cytotoxic T-lymphocytes, autologous transfer - June, p. 165
Cytovene (use ganciclovir)
D4T - May, p. 130; Aug., p. 236; Nov., p. 331
DDC - Apr., p. 103; Sep., p. 257, 264; Oct., p. 290; Dec., p. 363
DDI - June, p. 168; Sep., p. 257, 263; Dec., p. 363
DDI plus AZT - Mar., p. 76; Sep., p. 257
dehydrodidemnin A - May, p. 136
deoxyribonucleic guanidine (DNG) - June, p. 171
didemnins - May, p. 136
dideoxyadenosine, 2'-fluoro-2',3'- - Feb., p. 46
dideoxyinosine, 2'-fluoro-2',3'- - Feb., p. 46
dideoxythymidine, 2',3'-didehydro-2',3'- (use D4T)
Disabled Infectious Single Cycle (DISC) vaccines - Oct., p. 301
DMP-450 - Mar., p. 72
DP-178 - Oct., p. 300
E. coli enterotoxin adjuvants - Oct., p. 302
Ebola virus immune globulins - Sep., p. 267; Dec., p. 361
Engerix-B - Apr., p. 109
Epivir (use 3TC)
Eukaryotic Layered Vector System - Apr., p. 98
F-ddA - Feb., p. 46
F-ddI - Feb., p. 46
F105 antibody - July, p. 198
F58/A3 - July, p. 198
famciclovir - May, p. 138; Oct., p. 297; Dec., p. 355
Famvir (use famciclovir)
Fas/CD95 - Nov., p. 333
fialuridine (FIAU) - Mar., p. 76
foscarnet sodium - July, p. 193; Sep., p. 266
Foscavir (use foscarnet sodium)
furyl epoxy ketones - May, p. 136
ganciclovir - Feb., p. 42; Sep. 266, 267
ganciclovir, implant - Feb., p. 39; July, p. 202; Dec., p. 357
ganciclovir, oral - Feb., p. 33; May, p. 139; Oct., p. 295; Nov., p. 324
GEM 91 - Feb., p. 41
gene therapy, ex vivo - Apr., p. 107; July, p. 199
gene therapy, HIV-activated T-cells - Sep., p. 265; Nov., p. 328
gene therapy, HIV-infection - Nov., p. 330; Dec., p. 361
Gene-Modified Oligonucleotides (GMOs) - Nov., p. 332
GENEVAX vaccines - Aug., p. 231; Dec., p. 361
Geomatrix technology - Apr., p. 102
GS 504 (use cidofovir)
GS 840 - May, p. 132
GS 930 - May, p. 133
GS-1278 - Nov., p. 325
guanine-thymine oligonucleotides - Nov., p. 325
H-BIG - Sep., p. 260, 267
Havrix - Feb., p. 42; Mar., p. 67; Aug., p. 236
HBY 097 - Nov., p. 328
hepatitis A vaccines - Feb., p. 42; Mar., p. 67; May, p. 129; Aug., p. 236
hepatitis B drugs - Sep., p. 265
hepatitis B gene therapy - Feb., p. 46; Apr., p. 98
hepatitis B immune globulin - Sep., p. 260, 267
hepatitis B peptide/MHC receptor vaccines - Nov., p. 330
hepatitis B reverse transcriptase inhibitors - Apr., p. 109
hepatitis B virus vaccines - Apr., p. 109; June, p. 171
hepatitis C drugs - Sep., p. 265
hepatitis C virus diagnostics - May, p. 141; Nov., p. 335; Dec., p. 366
hepatitis C virus vaccines - Mar., p. 77; May, p. 142
hepatitis G virus vaccines - Feb., p. 38; Mar., p. 77; May, p. 142
HGP-30 - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Nov., p. 331
HIV antisense oligonucleotides - Feb., p. 41
HIV apoptosis inhibitors - May, p. 136
HIV diagnostics - May, p. 142; July, p. 205; Sep., p. 269
HIV drug combinations - Oct., p. 300
HIV envelope peptide vaccines - June, p. 170
HIV gene therapy vaccines - Apr., p. 98; Sep., p. 265; Oct., p. 296; Nov., p. 328, 330; Dec., p. 361
HIV glycoproteins - Oct., p. 302
HIV glycosidase inhibitors - May, p. 139; Nov., p. 328
HIV gp120 monoclonal antibodies - July, p. 197, 198
HIV gp120 peptides - July, p. 201
HIV gp160 vaccines - May, p. 137
HIV gp41 vaccines - Oct., p. 300
HIV immune globulins - Feb., p. 40; July, p. 198; Sep., p. 260
HIV Immunotherapeutic - Feb., p. 37; Mar., p. 74; June, p. 170; Oct., p. 298
HIV integrase inhibitors - Nov., p. 325, 333
HIV neutralizing antibodies - Nov., p. 328
HIV p17 vaccines - Apr., p. 102; May, p. 140; Aug., p. 235; Oct., p. 299; Nov., p. 331
HIV p17/p24:Ty-VLP vaccines - July, p. 197
HIV p45 and p80 - Dec., p. 364
HIV p7 nucleoprotein - Apr., p. 109
HIV peptide/MHC receptor vaccines - Oct., p. 300; Nov., p. 330
HIV protease inhibitors - Feb., p. 37; Mar., p. 72, 73; May, p. 137, 140; Aug., p. 232, 233, 235; Oct., p. 290, 291, 298; 299; Nov., p. 323; Dec., p. 353; 356
HIV protein-tyrosine kinase inhibitors - Dec., p. 366
HIV Tat inhibitors - Feb., p. 40; Oct., p. 299
HIV tyrosine kinase inhibitors - July, p. 202
HIV Universal Antiviral Binding technology - June, p. 166
HIV vaccines - July, p. 196; Nov., p. 331, 333; Dec., p. 364
HIV vaccines, canarypox virus vectors - June, p. 164
HIV vaccines, inactivated core - Feb., p. 37; Mar., p. 74; June, p. 170; Oct., p. 298
HIV vaccines, live - Feb., p. 42; May, p. 131; July, p. 203
HIV vaccines, prophylactic - June, p. 172
HIV zinc finger inhibitors - Aug., p. 238
HIV-1 envelope/beta-galactosidase vaccines - Sep., p. 260
HIV-1 gp120 C4-V3 peptide vaccines - Sep., p. 262
HIV-2 live vaccines - July, p. 194
HIV-infected cell apoptosis inducers - July, p. 202
HIV-IT (V) - Apr., p. 98; Oct., p. 296
HIVase-1 - Apr., p. 99
HIVID (use DDC)
HIVIG - Sep., p. 260
HNK20 - Oct., p. 294
HPMPC (use cidofovir)
HPV drugs - June, p. 163
HPV enzyme inhibitors - Apr., p. 103
HPV gene therapy vaccines - Dec., p. 361
HPV vaccines - Feb., p. 41; June, p. 163; Oct., p. 296; Nov., p. 335; Dec., p. 360
HSV gD vaccines - Sep., p. 260
HSV gD2 gene therapy vaccines - Dec., p. 361
HTLV-I diagnostics - Sep., p. 266
Human Anti-Cytomegalovirus Antibody - Nov., p. 327
human growth hormone, recombinant - Feb., p. 42
hydroxyurea - Sep., p. 263
hypericin - Apr., p. 104; May, p. 139
hyperthermia, extracorporeal - May, p. 138
Immupath - Feb., p. 40
indinavir sulfate - Mar., p. 72, 73; Aug., p. 233; Oct., p. 291, 298; Dec., p. 362
Infergen - Aug., p. 233; Nov., p. 330
influenza A virus, naked DNA vaccines - July, p. 203
influenza vaccines - Oct., p. 299; Apr., p. 108, 109; May, p. 138; June, p. 164, 169; Oct., p. 299; Nov., p. 330, 331; Dec., p. 363
interferon alfa-n3 - Feb., p. 46; May, p. 139; June, p. 169; Dec., p. 360
interferon, alpha-2a - May, p. 139; June, p. 171
interferon, alpha-2b - May, p. 139; Aug., p. 234
interferon, beta - Apr., p. 104; May, p. 135
interferon-alpha, concensus - Aug., p. 233; Nov., p. 330
interferon-alpha, injection - Oct., p. 296
interferon-alpha, oral - Nov., p. 331
interleukin-12 (IL-12) - July, p. 200; Oct., p. 298; Nov., p. 329
interleukin-16 (IL-16) - Dec., p. 358
interleukin-2 (IL-2) gene therapy - Sep., p. 270
interleukin-2 (IL-2) - Mar., p. 70; Sep., p. 279; Oct., p. 291
intracellular adhesion molecule-1 (ICAM-1) - Oct., p. 295
Intron A (use interferon, alpha-2b)
Invirase (use saquinavir)
ISIS 2922 - May, p. 131; Oct., p. 293
ISIS 5320 - Nov., p. 335
KNI-272 - Mar., p. 72
L-735,524 (use indinavir sulfate)
lamivudine (see also 3TC) - Aug., p. 227; Nov., p. 326, 334
LeukoVir-MB Filter - Nov., p. 331
Lidakol, intravaginal - May, p. 137, 138; Oct., p. 293
liposomal vaccine adjuvant - Apr., p. 109
lymphocyte LFA-1 monoclonal antibodies - Oct., p. 297
marine drugs - May, p. 136; Aug., p. 236
MEDI-491 - Apr., p. 97
MEDI-493 - Nov., p. 327
methylene blue dye - Nov., p. 331
MF59 - Oct., p. 292
MIP1-alpha - Dec., p. 358
MIP1-beta - Dec., p. 358
MK-639 (use indinavir sulfate)
monophosphoryl lipid A - Oct., p. 299
MSL-109 - Nov., p. 327
n-docosanol (use Lidakol)
naphthalene sulfonates - May, p. 134
Natural Alpha Interferon - Dec., p. 360
nevirapine - Apr., p. 103; Dec., p. 362, 363
nucleic acid sequence based amplification (NASBA) - Dec., p. 366
nystatin, liposomal - Mar., p. 75; Nov., p. 325
oligonucleotides, Zyn-Linker derivatives - Dec., p. 364
Optivax System - Sep., p. 270; Nov., p. 335
OraSure saliva collection devices - May, p. 142
parvovirus B19 virus-like particle vaccine - Apr., p. 97
Peptide T - Nov., p. 329
phosphonoformic acid, trisodium salt (use foscarnet sodium)
photoinactivation, blood - Sep., p. 270
PIC 024 - May, p. 134
PM92131 - May, p. 136
PMPA - Nov., p. 325
PN355 - July, p. 202; Dec., p. 366
podophyllin - Oct., p. 296
podophyllotoxin - Apr., p. 105
polycationic DNA analogs - June, p. 171
PRO 542 - June, p. 166
PRO 2000 - May, p. 134
proanthocyanidin polyphenolic oligomer - June, p. 162
Proleukin (use interleukin-2)
Proteinoid Oral Drug Delivery System - June, p. 169; Nov., p. 331
ProVax - Nov., p. 333; Dec., p. 364
Provir - June, p. 162
QS-21 Stimulon - Sep., p. 260; Oct., p. 299
RANTES - Dec., p. 358
RBC-CD4 - Aug., p. 235
RespiGam (use RSVIG-IV)
respiratory syncytial virus immune globulin-intravenous (use RSVIG-IV)
Reticulose - Feb., p. 43
Retrovir (use AZT)
ribavirin - Mar., p. 75; Aug., p. 234
ribonucleic guanidine - June, p. 171
ribozyme gene therapy - Mar., p. 76; Apr., p. 99
rimantadine - Feb., p. 43
ritonavir - Oct., p. 290, 298; Dec., p. 362, 364
Roferon A (use interferon, alpha-2a)
rotavirus vaccines, live oral - Apr., p. 100
RSV monoclonal antibodies - Oct., p. 294; Nov., p. 327
RSV vaccines - Nov., p. 327
RSVIG-IV - June, p. 168; Aug., p. 228; Nov., p. 327; Dec., p. 364
saliva, anti-HIV proteins - May, p. 136
saquinavir - Mar., p. 72; Apr., p. 103; June, p. 161; July, p. 195, 203; Aug., p. 235; Sep., p. 264; Oct., p. 290, 298; Nov., p. 323; Dec., p. 353
Scriptene - Feb., p. 42
secretory leukocyte protease inhibitor (SLPI) - May, p. 136
Serostim (use human growth hormone, recombinant)
single-chain antibody fusion protein immunotoxins - Mar., p. 75
SIV BCG vector vaccines - Nov., p. 333
SIV vaccine, live attenuated (SIVÆ3) - May, p. 133
SMART antibodies - Nov., p. 327
solvent/detergent inactivation - Apr., p. 105
SP-303 (use Provir)
SPC3 - July, p. 201
stavudine (use D4T)
systemic lupus erythematosus (SLE) antibodies - Sep., p. 260
T-20 - Oct., p. 300
T30177 - Mar., p. 75
TA-GW HPV vaccine - Oct., p. 301
Taq DNA polymerase - Feb., p. 45
Theradigm - Oct., p. 300; Nov., p. 330
thiacytidine, (-)2',3'-dideoxy-3'- (use 3TC)
thymosin alpha 1 - Feb., p. 41; June, p. 171; Nov., p. 331
TLC A-60 - Apr., p. 109
TRAx CD4 Test Kit - July, p. 204
triple helix oligonucleotides - Mar., p. 75
U-103,017 - Mar., p. 72
universal T-cell transplants - Nov., p. 328
vaccine adjuvants - July, p. 200; Sep., p. 270; Oct., p. 299, 302
vaccines, T-cell activation - Dec., p. 363
valacyclovir hydrochloride - Apr., p. 101; Aug., p. 225; Dec., p. 356
Valtrex (use valacyclovir hydrochloride)
Vaqta - May, p. 129; Aug., p. 236
Varicella Virus Vaccine Live - Mar., p. 65; Apr., p. 104; July, p. 204
Venezuelan equine encephalitis vaccines - July, p. 205
Videx (use DDI)
VIMRxyn (use hypericin)
Viracept (use AG1343)
viral inactivation, blood products - Nov., p. 331
Viralex - Apr., p. 105
Virazole (use ribavirin)
VISTIDE (use cidofovir)
Vitrasert Implant (use ganciclovir, implant)
VX-478 - Mar., p. 72; May, p. 140; Aug., p. 233; Dec., p. 356
xenotransplantation - May, p. 140; Aug., p. 230
ZADAXIN (use thymosin alpha 1)
Zerit (use D4T)
zidovudine (use AZT)
Zovirax (use acyclovir)
Zyn-Linker oligonucleotide derivatives - Dec., p. 364
adenoviruses - Oct., p. 298
AIDS-related wasting - Feb., p. 42
bovine viral diarrhea virus - Apr., p. 104
canine oral papillomavirus (COPV) - Dec., p. 360
canine parvovirus - Aug., p. 236
cervical cancer - Feb., p. 4; May, p. 139; June, p. 163, 169
chickenpox - Mar., p. 65
CMV disease - May, p. 133, 135, 139; Sep., p. 260, 267; Oct., p. 292; Nov., p. 324, 333
CMV retinitis - Feb., p. 33, 38, 39; Apr., p. 101; May, p. 131, 133; July, p. 202; Sep., p. 260, 266, 267; Oct., p. 292, 293, 295; Nov., p. 327; Dec., p. 357
Ebola virus - Sep., p. 267; Dec., p. 361
Epstein-Barr Virus - Nov., p. 330
GB viruses - Apr., p. 103
genital warts (see also HPV) - Feb., p. 41, 46; Apr., p. 105; May, p. 139; Sep., p. 264; Oct., p. 296, 301; Dec., p. 364
hepatitis A - Feb., p. 42; Mar., p. 67; May, p. 129; June, p. 162; Aug., p. 236
hepatitis B - Feb., p. 41, 46; Mar., p. 76; Apr., p. 98, 104, 105, 109; May, p. 132; June, p. 171; Sep., p. 260, 262, 265, 267; Nov., p. 326, 330, 334
hepatitis C - Feb., p. 44, 46; Mar., p. 75, 77; Apr., p. 104; May, p. 139, 141, 142; Aug., p. 233, 234; Sep., p. 265; Nov., p. 330, 335; Dec., p. 360, 366
hepatitis E - Nov., p. 332
hepatitis G - Feb., p. 38; Mar., p. 77; May, p. 142; Sep., p. 263
hepatitis viruses - Apr., p. 103
hepatitis X (use hepatitis G)
herpes simplex virus (use HSV; HSV-1 for oral; HSV-2 for genital herpes)
herpes zoster (use varicella-zoster virus)
HIV/AIDS - Feb., p. 35, 37, 40, 41, 42, 43, 46; Mar., p. 70, 72, 73, 74, 75, 76, 78; Apr., p. 98, 102, 103, 105, 109; May, p. 130, 131, 134, 136, 137, 138, 139, 140, 142; June, p. 161, 164, 165, 166, 168, 170, 171, 172, 173; July, p. 194, 195, 196, 197, 198, 199, 200, 201, 203, 204, 205; Aug., p. 227, 230, 231, 232, 233, 235, 236, 238; Sep., p. 260, 262, 263, 264, 265, 266, 267, 268, 269, 270; Oct., p. 289, 290, 291, 296, 297, 298, 299, 300, 302; Nov., p. 321, 323, 325, 328, 329, 330, 331, 332, 333, 335, 336; Dec., p. 353, 356, 358, 361, 362, 363, 364, 365, 366
HPV (see also genital warts, cervical cancer) - Apr., p. 103, 105; May, p. 133; June, p. 163, 169; Sep., p. 268; Nov., p. 335; Dec., p. 361
HSV - Apr., p. 102; May, p. 135; Dec., p. 361
HSV-1 (oral herpes) - May, p. 138; July, p. 193; Oct., p. 293, 297
HSV-2 (genital herpes) - Feb., p. 36, 40; May, p. 133, 138; July, p. 193; Sep., p. 260; Dec., p. 355, 356, 363
HTLV-I - Sep., p. 266
human herpesvirus-6 (HHV-6) - May, p. 135
human herpesvirus-8 (HHV-8) - Oct., p. 294
human papillomavirus (use HPV)
influenza A - Feb., p. 42, 43; June, p. 164; July, p. 203
influenza A and B - Apr., p. 108, 109; May, p. 138; June, p. 169; Oct., p. 299; Nov., p. 330; Dec., p. 363
KaposiÕs sarcoma herpesvirus (KSHV) - Oct., p. 294
non-HodgkinÕs lymphoma - June, p. 171
parvovirus - Apr., p. 97, 105
rabies - Sep., p. 268
respiratory syncytial virus (RSV) - May, p. 135; June, p. 162, 168; Aug., p. 228; Oct., p. 294; Nov., p. 327; Dec., p. 364
retinal pigmented epithelial stippling - May, p. 131
rhinoviruses - Oct., p. 295
rotavirus gastroenteritis - Apr., p. 100
Sindbis virus vectors - Apr., p. 98
SIV - May, p. 133, 137; Nov., p. 325, 333
varicella-zoster virus (VZV) - Mar., p. 65; Apr., p. 104; May, p. 135; Aug., p. 225; July, p. 204
Venezuelan equine encephalitis - July, p. 205
ACTG 175 - Sep., p. 257
Anabolic Steroid Control Act of 1990 - June, p. 171
animal studies - July, p. 203
approvals, diagnostics - July, p. 204
approvals, FDA - Feb., p. 33, 42; Mar., p. 65, 67; Aug., p. 225; Nov., p. 321, 323, 324, 331; Dec., p. 353, 355, 356, 364
approvals, filings - May, p. 129, 139; Aug., p. 227, 228, 236; Sep., p. 264; Oct., p. 292; Nov., p. 330; Dec., p. 357, 364
approvals, Treatment INDs - Sep., p. 260
approvals, U.K. - May, p. 138, 139
blood products - Apr., p. 104, 105; Nov., p. 332
brain bioavailability - Dec., p. 356
canine studies - Aug., p. 236; Dec., p. 360
carcinogenicity - June, p. 171
CD4+ T-cell diagnostics - July, p. 204
clinical trials - Feb., p. 35, 37, 38, 39, 40, 41, 42; Mar., p. 65, 67, 70, 72, 73, 76; Apr., p. 97, 100, 102, 103, 104, 105, 108; May, p. 129, 130, 131, 132, 133, 134, 137, 138, 139, 140; June, p. 162, 164, 165, 168, 169, 170, 171, 172; July, p. 197, 198, 201, 202, 205; Aug., p. 225, 227, 228, 230, 231, 232, 233, 234, 235; Sep., p. 257, 262, 263, 265, 266, 267; Oct., p. 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300; Nov., p. 321, 323, 324, 325, 326, 327, 328, 329, 330, 331; Dec., p. 353, 356, 357, 360, 363, 364
clinical trials, halted - Feb., p. 43; Mar., p. 76; Apr., p. 101
clinical trials, pediatric - Mar., p. 76
Collaborative Research and Development Agreement (CRADAs) - Feb., p. 38, 46; Mar., p. 67; Apr., p. 97, 100, 106, 108; May, p. 135, 136; July, p. 199; Aug., p. 238; Sep., p. 263; Dec., p. 363, 366
Congressional investigations - Feb., p. 42
corporate linkages (see also licensing) - Feb., p. 42; Mar., p. 74, 76; Apr., p. 99, 109; May, p. 134, 135, 136, 140, 142; June, p. 169; July, p. 196; Aug., p. 234; Sep., p. 260, 265, 266, 267; Oct., p. 298; Nov., p. 327, 328, 330, 331; Dec., p. 361, 363
corporate mergers/acquisitions - Mar., p. 71, 75; Apr., p. 98; May, p. 139, 140; July, p. 199; Sep., p. 260, 265; Nov., p. 330, 332; Dec., p. 363
cost-recovery programs - Feb., p. 42
Costa Rica - May, p. 138
Delta trial - Oct., p. 289
drug combinations - July, p. 195; Sep., p. 257
drug usage recommendations - Feb., p. 43
epidemiologic studies - June, p. 171; July, p. 194
expanded access lotteries - June, p. 161, 170; July, p. 203; Aug., p. 233, 235, 236; Oct., p. 298; Dec., p. 364
federal contracts/grants - July, p. 205; Aug., p. 237; Sep., p. 268; Oct., p. 300; Nov., p. 333
funding disagreement - Aug., p. 235
General Agreement on Tariffs and Trade (GATT) - Mar., p. 78
Herpes Management System - Feb., p. 40
HIV diagnostics - Apr., p. 109
HIV in lymph nodes - Nov., p. 328
HIV strains, co-infection - July, p. 203
HIV testing, pregnant women - July, p. 205
HIV-infection, kinetics - Dec., p. 362
HIV-infection, remission - May, p. 131
insurance claims - Sep., p. 266
intermediate trials - June, p. 172
intramural research, NIH - June, p. 172
Japan - May, p. 140
licensing (see also corporate linkages) - Feb., p. 41, 46; Mar., p. 67, 77; Apr., p. 99, 100, 105, 106, 107, 109; May, p. 135, 136, 139, 140, 142; June, p. 168; July, p. 199, 202, 206; Aug., p. 234; Sep., p. 267, 270; Oct., p. 299, 301, 302; Nov., p. 327, 332, 335, 336; Dec., p. 361, 364, 365, 366
licensing opportunities - Apr., p. 109; Aug., p. 238
market size - Nov., p. 332
mitochondrial toxicity - Mar., p. 76
mucosal delivery - Nov., p. 331, 335
mucosal immunity - June, p. 170; Sep., p. 270; Oct., p. 298, 302
new viruses - Feb., p. 38, 44; Mar., p. 77; Apr., p. 103; Sep., p. 263; Oct., p. 294
oligonucleotide synthesis - Feb., p. 41
passive immunization - Feb., p. 40; July, p. 198; Sep., p. 260, 267; Oct., p. 294
patent claims, clinical utility - Feb., p. 45
patent disputes - Feb., p. 42, 44, 45, 46; Apr., p. 105, 109; May, p. 141; June, p. 173; Sep., p. 269, 279; Nov., p. 334, 335; Dec., p. 366
Points to Consider documents - Sep., p. 267
primate studies - May, p. 133; July, p. 194; Oct., p. 295; Nov., p. 325, 331; Dec., p. 361
reasonable pricing (licensing) - Apr., p. 106
rejections, FDA - Mar., p. 75
resistance, HIV protease inhibitors - July, p. 195
rodent models, hepatitis - Sep., p. 265
rodent studies - Oct., p. 298
screening - Feb., p. 41; Apr., p. 103, 109; May, p. 136, 140; June, p. 172; July, p. 202; Aug., p. 238; Sep., p. 265; Oct., p. 300; Nov., p. 335
Sexually Transmitted Diseases Cooperative Res. Centers - Sep., p. 268
South Korea - Feb., p. 41
spermicides - May, p. 137
synthesis difficulties - Mar., p. 72
Taiwan - Feb., p. 41
TH1 cellular immune responses - July, p. 200
Thailand - May, p. 139
thymidine kinase gene insertion - Feb., p. 42
transgenic animals - Sep., p. 267; Nov., p. 336
translation inhibition - Feb., p. 41
Treatment IND - Feb., p. 42
triple helix structures - June, p. 171
universal vaccination - July, p. 204
veterinary vaccines - Oct., p. 301
virology Web pages - Sep., p. 269
viruses, oncogenic - June, p. 163
yeast expression system - June, p. 171; Oct., p. 302; Dec., p. 364
Zaire - Sep., p. 267
.